Global C-MET / HGF Inhibitors Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application

c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several biological responses collectively known as invasive growth program. These responses are elicited due to activation of several pathways such as RAS pathway, PI3K pathway, STAT pathway, beta-catenin pathway and Notch pathway. However, dysregulation of the HGF/c-MET signaling pathway has been associated with the progression of cancers through activation of oncogenic pathways, angiogenesis and metastasis.
The major cancers such as breast, colon and non-small-cell lung carcinoma (NSCLC) are being examined for efficacy with c-MET / HGF inhibitors. Several small molecule c-Met kinase inhibitors have demonstrated clinical efficacy in cancer treatment and many clinical trials are underway. However, as the small molecule inhibitors lack specificity or selectivity they can cause toxicity. Therefore, researchers are increasing focus to develop antibody therapeutics against c-Met or HGF.

Market Analysis and Insights: Global C-MET / HGF Inhibitors Market
In 2020, the global C-MET / HGF Inhibitors market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global C-MET / HGF Inhibitors Scope and Market Size
The global C-MET / HGF Inhibitors market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global C-MET / HGF Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.

Segment by Type
C-Met Biologic Inhibitors
Small Molecule C-Met Inhibitors
HGF Antagonist Antibodies
C-Met Antagonist Antibodies(MetMAb)
HGF Kringle Variant Antagonists

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales

By Company
Abxign
Abbott Laboratories
Amgen
ArQule
Astex Therapeutics
AVEO Pharmaceuticals
Bristol-Myers Squibb(BMS)
Chroma Therapeutics
Daiichi Sankyo
Deciphera Pharmaceuticals
Eisai
Eli Lilly
Exelixis
Genmab
Galaxy Biotech
GlaxoSmithKline(GSK)
Hutchison MediPharma
Johnson & Johnson
Kringle Pharmaceuticals
Merck
Methylgene
Novartis
Pfizer
ProMetic BioTherapeutics
Takeda Pharmaceutical

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Frequently Asked Questions